{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T15:56:11Z","timestamp":1700322971787},"reference-count":17,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2001,11,12]],"date-time":"2001-11-12T00:00:00Z","timestamp":1005523200000},"content-version":"vor","delay-in-days":195,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biopharm &amp; Drug Disp"],"published-print":{"date-parts":[[2001,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The absorption rate of <jats:italic>\u03b1<\/jats:italic>\u2010human atrial natriuretic peptide (<jats:italic>\u03b1<\/jats:italic>\u2010hANP) after intranasal (i.n.) administration to rats was estimated from the plasma profile and pharmacological effect (diuretic effect) using a pharmacokinetic (PK) model and a PK\u2013pharmacodynamic (PD) model involving data obtained after intravenous (i.v.) bolus injection. The plasma concentrations of <jats:italic>\u03b1<\/jats:italic>\u2010hANP after i.v. administration at different doses were fitted to a two\u2010compartment PK model with zero\u2010order excretion and input of endogenous <jats:italic>\u03b1<\/jats:italic>\u2010rat atrial natriuretic peptide (<jats:italic>\u03b1<\/jats:italic>\u2010rANP) and two elimination processes represented by Michaelis\u2013Menten and first\u2010order kinetics. However, the saturable process was ignored at low doses. The plasma concentrations after low doses via the i.n. route could also be expressed by this model, but with first\u2010order absorption, so that an absorption rate constant was calculated using a deconvolution method. In addition, the diuretic effect plotted against the i.v. dose was represented by the Hill equation and showed an anti\u2010clockwise hysteresis loop versus the plasma concentration. These results suggest that the diuretic effect could be estimated by a PK\u2013PD model having an \u2018effect\u2019 compartment or a homeostatic system. Such a PK\u2013PD model accurately expressed the diuretic effect of <jats:italic>\u03b1<\/jats:italic>\u2010hANP at all doses after i.v. and i.n. administrations. The resulting absorption rate constant calculated using the PK\u2013PD model agreed closely with that obtained by the PK model alone. The absorption rate and simulated diuretic effect suggest that, for i.n. administration of <jats:italic>\u03b1<\/jats:italic>\u2010hANP, a higher absorption rate constant causes a more potent diuretic effect (a dramatic effect over the early period), whereas greater bioavailability is associated with a better hypotensive effect (sustained effect). Copyright \u00a9 2001 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/bdd.272","type":"journal-article","created":{"date-parts":[[2002,8,25]],"date-time":"2002-08-25T16:22:28Z","timestamp":1030292548000},"page":"137-146","source":"Crossref","is-referenced-by-count":2,"title":["Estimation of absorption rate of <i>\u03b1<\/i>\u2010human atrial natriuretic peptide from the plasma profile and diuretic effect after intranasal administration to rats"],"prefix":"10.1002","volume":"22","author":[{"given":"Misao","family":"Miyamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Tsukune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiichi","family":"Hori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruaki","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideshi","family":"Natsume","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Sugibayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuori","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,11,12]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"87","article-title":"Absorption across the nasal mucosa of animal species. Compounds applied and mechanisms involved","volume":"12","author":"Fisher AN","year":"1990","journal-title":"Prog Drug Metab."},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0939-6411(97)00101-X"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018901302450"},{"key":"e_1_2_1_5_2","volume-title":"Nasal Systemic Drug Delivery","author":"Chien YW","year":"1989"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.21.866"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015894910416"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-5173(98)00367-6"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.2510140805"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.17.316"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0168-3659(90)90146-K"},{"key":"e_1_2_1_12_2","first-page":"737","article-title":"Human atrial natriuretic peptide (hANP), human brain natriuretic peptide (hBNP)","volume":"53","author":"Tsujino M","year":"1995","journal-title":"Nippon Rinsho"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-5173(81)90058-2"},{"key":"e_1_2_1_14_2","first-page":"765","article-title":"Some pharmacokinetical aspects on the drug development of \u03b1\u2010human atrial natriuretic peptide ( \u03b1\u2010hANP)","volume":"8","author":"Hayashi Y","year":"1993","journal-title":"Xenobio Metab Dispos"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1979253358"},{"key":"e_1_2_1_16_2","first-page":"498","article-title":"Pharmacokinetics and pharmacodynamics of \u03b1\u2010human atrial natriuretic peptide (\u03b1\u2010hANP)","volume":"3","author":"Ohnuma N","year":"1988","journal-title":"Xenobio Metab. Dispos"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI112159"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-395640-8.50013-5"}],"container-title":["Biopharmaceutics &amp; Drug Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbdd.272","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bdd.272","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T15:12:20Z","timestamp":1700320340000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/bdd.272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,5]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2001,5]]}},"alternative-id":["10.1002\/bdd.272"],"URL":"https:\/\/doi.org\/10.1002\/bdd.272","archive":["Portico"],"relation":{},"ISSN":["0142-2782","1099-081X"],"issn-type":[{"value":"0142-2782","type":"print"},{"value":"1099-081X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,5]]}}}